Provided by Tiger Trade Technology Pte. Ltd.

Adagene

3.29
0.0000
Post-market: 3.370.0800+2.43%17:43 EST
Volume:61.70K
Turnover:211.36K
Market Cap:155.06M
PE:-5.12
High:3.53
Open:3.31
Low:3.27
Close:3.29
52wk High:3.53
52wk Low:1.30
Shares:47.13M
Float Shares:12.73M
Volume Ratio:0.63
T/O Rate:0.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6428
EPS(LYR):-0.7423
ROE:-63.26%
ROA:-24.89%
PB:4.09
PE(LYR):-4.43

Loading ...

Adagene to Participate in Two Upcoming Investor Conferences

GlobeNewswire
·
Feb 17

Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Tyra Bioscience (TYRA)

TIPRANKS
·
Feb 15

Adagene (ADAG): De-Risked CTLA-4 Asset, Emerging Regulatory Clarity, and Strategic Partnerships Underpin Buy Rating

TIPRANKS
·
Feb 09

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Adagene (ADAG) and Johnson & Johnson (JNJ)

TIPRANKS
·
Jan 26

Adagene Reports $74.5 Million Year-End Cash and Sets 2026 Clinical Milestones

Reuters
·
Jan 26

Press Release: Adagene Provides Business Update and 2026 Objectives

Dow Jones
·
Jan 23

LifeSci Capital Sticks to Their Buy Rating for Adagene (ADAG)

TIPRANKS
·
Jan 20

Adagene's Muzastotug Gets FDA Fast Track in Colorectal Cancer

MT Newswires Live
·
Dec 17, 2025

Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)

Reuters
·
Dec 16, 2025

Adagene Reports Promising Responses for Muzastotug in Combination with Pembrolizumab

Reuters
·
Dec 16, 2025

Adagene Initiated at Buy by Guggenheim

Dow Jones
·
Nov 24, 2025

Guggenheim Initiates Coverage on Adagene With Buy Rating, $9 Price Target

MT Newswires Live
·
Nov 24, 2025

Adagene Signs Licensing Agreement With Third Arc Bio for SAFEbody Technology

Reuters
·
Nov 13, 2025

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

GlobeNewswire
·
Oct 31, 2025

Adagene’s Innovative Cancer Study: A Potential Game-Changer in Oncology

TIPRANKS
·
Oct 28, 2025

Adagene Initiated at Buy by LUCID CAPITAL MARKETS

Dow Jones
·
Sep 18, 2025

Adagene initiated with a Buy at Lucid Capital

TIPRANKS
·
Sep 18, 2025

Adagene expands SAFEbody collaboration, license agreement with Exelixis

TIPRANKS
·
Sep 16, 2025

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

GlobeNewswire
·
Sep 16, 2025

Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China

Reuters
·
Sep 05, 2025